Crit Care Resusc. 2018 Mar;20(1):6-14.
Nutrition is routinely provided to critically ill patients who are mechanically ventilated and remain in the intensive care unit for more than a few days. Nasogastric feeding, which is standard practice for patients who are unable to tolerate oral nutrition, typically delivers less than 60% of the recommended energy requirements. It remains uncertain whether the delivery of about 100% of the recommended energy goals via the enteral route will affect survival and other important clinical outcomes.
To describe the protocol for a large-scale, multicentre, double-blind, randomised, controlled, parallelgroup, phase 3 clinical trial to determine if augmentation of calorie delivery using an energy-dense enteral nutrition formulation in mechanically ventilated patients increases 90-day survival when compared with routine care.
4000 patients who are mechanically ventilated and are expected to receive enteral nutrition for more than 2 days are to be randomised to an energy-dense formulation (1.5 kcal/mL) or routine enteral feed formulation (1 kcal/mL), given at the same rate. The primary outcome is 90-day all-cause mortality. Secondary outcomes include cause-related mortality up to Day 90; all-cause mortality at hospital discharge and at Days 28 and 180 after randomisation; and ventilator-, vasopressorand renal replacement-free days to Day 28. Health-related quality of life and functional assessments will be conducted at Day 180 after randomisation.
The results of this trial are expected to determine whether increased energy delivery, using an energy-dense formula can improve clinically meaningful outcomes, including survival.
对于接受机械通气且在重症监护病房停留超过数天的重症患者,通常会提供营养支持。对于无法耐受口服营养的患者,鼻胃管喂养是标准做法,但通常只能提供不到推荐能量需求的60%。通过肠内途径提供约100%的推荐能量目标是否会影响生存率和其他重要临床结局仍不确定。
描述一项大规模、多中心、双盲、随机、对照、平行组3期临床试验的方案,以确定与常规护理相比,在机械通气患者中使用能量密集型肠内营养制剂增加热量供应是否能提高90天生存率。
4000例接受机械通气且预计接受肠内营养超过2天的患者将被随机分配到能量密集型制剂组(1.5千卡/毫升)或常规肠内喂养制剂组(1千卡/毫升),以相同速率给予。主要结局是90天全因死亡率。次要结局包括至第90天的病因相关死亡率;随机分组后出院时、第28天和第180天的全因死亡率;以及至第28天无呼吸机、血管活性药物和肾脏替代治疗的天数。将在随机分组后第180天进行健康相关生活质量和功能评估。
该试验结果有望确定使用能量密集型配方增加能量供应是否能改善包括生存在内的具有临床意义的结局。